STALEVO MAY HELP MORE THAN STANDARD THERAPY FOR EARLY PARKINSON'S DISEASE
April 15, 2008
April 15, 2008
BASEL, Switzerland, April 15 -- The University of South Florida issued the following news release:
A new study in patients with early Parkinson's disease demonstrates that Stalevo (a combination of levodopa/carbidopa/entacapone) provides better symptom control and greater improvements in activities of daily living than levodopa/carbidopa, the most widely-used current therapy.
The FIRST STEP study was presented today at the American Academy of Neurology Annual Meetin . . .
A new study in patients with early Parkinson's disease demonstrates that Stalevo (a combination of levodopa/carbidopa/entacapone) provides better symptom control and greater improvements in activities of daily living than levodopa/carbidopa, the most widely-used current therapy.
The FIRST STEP study was presented today at the American Academy of Neurology Annual Meetin . . .